The Latest

In today’s healthcare landscape, independent practices face mounting financial pressures—from reimbursement challenges to rising operational costs. Yet, amid these hurdles, innovative solutions like RegenMed are transforming how physicians can generate sustainable revenue and enhance their practice’s value — all without significant investment or added burden.Introducing RegenMed’s Physicians-Owned Circles (POCs): a game-changing, turnkey platform designed to empower clinicians to own, monetize, and leverage their real-world data efficiently and affordably.Why Choose RegenMed Circles?Minimal Upfront CostEach POC costs as little as $5 per case and $35 monthly — an accessible fee that ensures virtually no risk for your practice. This low barrier enables you to start capturing and monetizing valuable data immediately.High-Quality Data at Low CostOur patented platform streamlines data collection, requiring less than a minute per case, so your clinical workflow remains uninterrupted. The result? High-quality, statistically significant datasets developed with minimal effort.Shared Revenue and OwnershipAs a member, you own 75% of the value generated from your dataset’s licensing, royalties, and other monetization streams. Additionally, physicians retain 85% of dataset ownership, turning your clinical insights into tangible financial returns.Multiple Revenue StreamsBeyond dataset monetization, POC participation opens avenues for consulting fees, publication opportunities, and enhanced patient engagement — further diversifying your income potential and practice reputation.Long-Term Practice EquityUnlike traditional models that leave practices with only patient fees and no residual value, RegenMed’s approach builds practice equity through high-quality datasets — assets that grow in value over time and can be monetized repeatedly.Scalable and FlexibleStart with one POC or multiple — scale your data assets as your practice grows. Our study protocols are tailored to your specialty, ensuring relevance and maximum value.Discover how your practice can benefit today — visit RegenMed’s POC Library or contact us to learn more about building your practice’s data-driven revenue streams.

Are you a provider specializing in Women's Health Shockwave therapy? Want to elevate your clinical practice, own your data, and unlock new financial and research opportunities — all while collaborating within a dedicated community? RegenMed is proud to introduce our Women’s Health Shockwave Circles, a high-quality, low-cost, turnkey solution designed specifically for physicians like you. Led by Principle Investigator Amy Vander Linden, this community offers a unique platform to share insights, accelerate innovation, and generate real-world evidence to advance women’s health treatments. Join a network of forward-thinking physicians committed to improving patient outcomes and shaping the future of women’s health interventions. As part of the Circle, you'll gain access to: Proprietary data ownership and controlRobust clinical and financial insightsCollaborative opportunities with leading expertsA supportive community dedicated to advancing women's health Together, we can drive impactful change in Women's Health Shockwave therapy. Elevate your practice, contribute to groundbreaking research, and be part of a movement that puts physicians at the center of innovation. Learn more about Dr. Amy Vander Linden’s Circles below: Female Reproductive System/Clitoral Enhancement/Shockwave/FSFI Pelvis/Pelvic Floor Dysfunction/Shockwave/PUF+ICIQ-UI+BPI Female Reproductive System/Endometriosis/Shockwave/SF-12+FSFI+BPI Female Reproductive System/Polycystic Ovarian Syndrome (PCOS)/Shockwave/SF-12+FSFI+BPI

Physician Group Sponsors — now you can easily establish a clinically-impactful and revenue-producing library of proprietary data registries. A Circles Registry Program will materially advance clinical excellence, ethically generate new funding, and add real value to member physicians.What Sets Circles Apart?Clinically Relevant and Peer-Reviewed: Observational Protocols tailored to real-world practice, covering specific anatomical regions, pathologies, and outcomes.Top-Tier Data Quality: Comparable to traditional clinical trials — compliant with HIPAA, GDPR, and more — fully validated, and continuously refreshed with new data.Proprietary & Valuable: No data ownership conflicts — highly licenseable datasets that drive innovation and revenue.Financial & Strategic BenefitsTap into the $60B healthcare data analytics market, growing at 20% annually.License quality datasets to manufacturers, insurers, AI developers, and research centers — 85% of license fees go directly to your physician group.Enhance standards of care, expand service lines, and boost your valuation for future exits.Strengthen negotiating power with payers, improve CMS compliance, and unlock new contracting opportunities.Minimal Effort, Maximum ImpactEasy setup with patented platforms (#inCytes™ & #Benchmarc™).Quick, cost-effective data collection — just $5 per case, $35/month subscription.Engage physicians with minimal burden while fostering collaboration and professional growth.Offer patients personalized feedback, improving engagement and satisfaction.Learn more in our one sheet: "Circles Registries For ASCs, IPGs, and IPAs"

Please join our CEO and Co-Founder for a presentation on our $100 bn addressable markets, ongoing market traction, and financial and per share projections. We look forward to engaging with our current investors in this exciting “Zero-to-One” company, and those who may be interested in joining them. Visit our Investors page for more details.

While the $60 billion healthcare data analytics industry expands rapidly, ASCs are failing to exploit their most valuable asset while others do so. This RegenMed video explains how any ASC can generate new revenue streams and asset value by capturing and monetizing real-world evidence (RWE) from routine patient care. Key sections of the video, with time codes, are:The Opportunity [0:18 – 1:14]Real-World Evidence — structured datasets generated from routine patient care — is in high demand across industry and research. The $60 billion healthcare data analytics industry is growing at a rate of over 20% annually. ASCs are not only uniquely positioned to contribute to this market, but to benefit from it financially. RWE licensors include product manufacturers, insurers, research centers, and AI models. Use cases for licenses include competitive intelligence, regulatory submissions, product innovation, legal compliance, value based care, social determinants of health, and health equity. ASCs Can Participate [1:15 – 2:26]ASCs already regularly enter EMR and other real-world data, and pay to do so. However, that data is being aggregated, manipulated, and licensed by others. However, and despite their high cost, RWE datasets synthesizing EMRs, prescription, insurance claim and other disparate sources are incomplete, unverifiable and generally clinically irrelevant. Using RegenMed’s patented Circles technology and processes, ASCs can now structure, aggregate, own and monetize that RWD themselves — without burdening staff or altering clinical workflows. Primary and well correlated datasets which are verifiably sourced from daily patient care – against a prospectively designed Observational Protocol – are far more clinically relevant and “fit-for-purpose” than current RWE offerings. They are therefore far more valuable.What Do Circles Datasets Look Like [2:27–3:40]This section shows two separate illustrative reports. One compares four different knee implant products over twelve months against KOOS Jr. scores in the context of total knee arthroplasty. The second compares two separate surgical techniques over 27 months against a VAS score in the context of total hip arthroplasty.Although these are orthopedics examples, Circles can be and are used to generate clinically and statistically significant datasets for any anatomical region, pathology, treatment protocol, and standardized or custom outcomes score – regardless of medical specialty. EBITDA and New Asset Potential For An Average ASC [3:40 – 6:04]Based on the stated assumptions, which of course will depend on the specific circumstances of each ASC, five Circles datasets generated by ten physicians can produce new annual EBITDA of $850,000 for a total cost of only $31,000 — a return on investment of 14x. Moreover, these five 6-month longitudinal Circles datasets represent asset value of $2.6 million on the stated assumptions. Finally, an ASC can continue to increase these income streams and asset value through continued outcomes capture, additional Observational Protocols relevant to its practice mix, and combining internal and external Circles datasets.ConclusionTo discuss your specific situation, please contact us. RegenMed is not a mere solutions vendor. It works with each Client as a long-term partner to develop meaningful clinical and financial returns on investment.Contact usRegenMed | www.rgnmed.comcircles@rgnmed.com